Please login to the form below

Not currently logged in
Email:
Password:

Danish biopharma company wins R&D award

Zealand Pharma has won the 2008 European Research & Development Company of the Year Award from Frost & Sullivan

Zealand Pharma A/S has won the 2008 European Research & Development Company of the Year Award from Frost & Sullivan, a global growth consulting firm. Zealand Pharma is involved in the discovery and development of innovative peptide-based drugs. It has been ranked top for demonstrating technological superiority in its field through market analysis based on interviews and extensive secondary research.

"It is an honour to be recognised by Frost & Sullivan", said David Solomon, head of Zealand Pharma A/S. "The European Research & Development Award highlights our company's ongoing achievements in its path to commercialising peptide-based drugs that treat unmet medical need in the areas of diabetes, metabolism, cardiovascular disease and gastrointestinal disorders such as Crohn's disease." 

The award recognises the ability of the company to successfully develop and introduce new technology, formulate a well-designed product family, and make significant product performance contributions to the industry.

All of Zealand's products target diseases and symptoms of significant unmet clinical need and commercial potential. 

Since 1999, Zealand's scientists have built a pipeline that includes five compounds in clinical development, three of which have been out-licensed to pharmaceutical companies, sanofi-aventis, Wyeth and Helsinn Healthcare.

18th March 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics